CN113493417A - Temozolomide intermediate compound VII - Google Patents
Temozolomide intermediate compound VII Download PDFInfo
- Publication number
- CN113493417A CN113493417A CN202010205396.9A CN202010205396A CN113493417A CN 113493417 A CN113493417 A CN 113493417A CN 202010205396 A CN202010205396 A CN 202010205396A CN 113493417 A CN113493417 A CN 113493417A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- temozolomide
- stirring
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 229960004964 temozolomide Drugs 0.000 title claims abstract description 40
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 claims abstract description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 90
- 238000006243 chemical reaction Methods 0.000 claims description 76
- 238000003756 stirring Methods 0.000 claims description 36
- 238000001816 cooling Methods 0.000 claims description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 2
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 32
- 239000012065 filter cake Substances 0.000 description 27
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- 238000005406 washing Methods 0.000 description 19
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 17
- 238000001035 drying Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229960000583 acetic acid Drugs 0.000 description 16
- 239000012362 glacial acetic acid Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000003828 vacuum filtration Methods 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000011259 mixed solution Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000000967 suction filtration Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 229960001701 chloroform Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 6
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 6
- 238000004537 pulping Methods 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000009776 industrial production Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000005457 ice water Substances 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- IKZLMSPFYNDYIL-UHFFFAOYSA-N (5E)-5-diazoimidazole-4-carboxamide Chemical compound NC(=O)C1=NC=NC1=[N+]=[N-] IKZLMSPFYNDYIL-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 231100000086 high toxicity Toxicity 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VYDWQPKRHOGLPA-UHFFFAOYSA-N 5-nitroimidazole Chemical compound [O-][N+](=O)C1=CN=CN1 VYDWQPKRHOGLPA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000007983 brain glioma Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229910004003 H5IO6 Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- VXJIMUZIBHBWBV-UHFFFAOYSA-M lithium;chloride;hydrate Chemical compound [Li+].O.[Cl-] VXJIMUZIBHBWBV-UHFFFAOYSA-M 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007243 oxidative cyclization reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention belongs to the field of pharmaceutical chemicals, and particularly relates to a temozolomide intermediate compound VII, which is a new intermediate VII obtained by performing one-step hydrolysis on an imidazole azo intermediate compound serving as a raw material and performing nucleophilic substitution on the hydrolyzed intermediate compound and p-nitrophenyl chloroformate.
Description
Technical Field
The invention belongs to the field of pharmaceutical chemicals, and particularly relates to a temozolomide intermediate compound VII.
Background
Temozolomide (Temozolomide), chemical name 8-carbamoyl-3-methylimidazole [5,1-d]-1,2,3, 5-tetrazin-4 (3H) -one of formula: c6H6N6O2(ii) a Molecular weight: 194.15, respectively; CAS registry number 85622-93-1, structural formula as follows:
temozolomide was first developed by the university of aston, uk, and later by the german pioneer pauya pharmaceutical, and was marketed in the united states in 1999. Pharmacological research proves that temozolomide is a novel medicine with better curative effect on brain glioma; has high bioavailability, can be orally taken, is easy to permeate blood brain barrier, has no superimposed toxicity compared with other medicines, and has wider anti-tumor spectrum. Currently, temozolomide is a better anticancer drug for treating brain glioma and malignant melanoma, and the capsule of temozolomide is approved in Europe and America to be used for treating malignant glioma.
The conventional synthesis method of temozolomide is to take 5-amino-1H-imidazole-4-formamide or hydrochloride thereof as a raw material to react with sodium nitrite, diazotize the raw material and then react with methyl isocyanate to prepare temozolomide (Journal of the Chemical Society, Perkin Transactions l, 1998, 10: l669-1775), 5-aminoimidazole-4-formamide reacts with excessive sodium nitrite under the conditions of low temperature and acidity to obtain 5-diazoimidazole-4-formamide 2, the compound 2 reacts with methyl isocyanate in a mixed solution of dimethyl sulfoxide and ethyl acetate for 2 days at normal temperature, and the temozolomide product with high purity and high yield is obtained through a bipolar intermediate 3.
Although the reaction has high atom utilization rate and high yield, the methyl isocyanate has high toxicity, the reaction conditions are difficult to control and transport, and certain difficulty is brought to production.
To avoid the use of isocyanates (Journal of the Chemical Society, Perkin Transactions 1, 2002, 16: 1877) -1880) the literature reports the formation of 5-nitroimidazole 4-acetonitrile by the reaction of 5-nitroimidazole with potassium cyanate in the presence of nitric acid, followed by a multi-step reaction to temozolomide. The method has high yield, avoids methyl isocyanate with high toxicity and unstable diazo compound 5-diazoimidazole-4-formamide, but has long synthetic route which is too complex and is not suitable for industrial production.
Chinese patent application CN103626772 reports that 5-aminoimidazole-4-formamide is used as a raw material, a compound 5 is synthesized through two-step reaction, and then temozolomide is generated through cyclization by an oxidation cyclization reagent, and the route is as follows:
although this process is short in steps and does not use 5-diazoimidazole-4-carboxamide with methyl isocyanate, the oxidative ring reagent is I2、ICl、ICl3And H5IO6The toxic dangerous reagent containing iodine is high, but the final yield is only 49.8%.
In conclusion, the temozolomide preparation methods have the problems of long route, low yield and low purity; the use of a highly toxic methyl isocyanate chemical reagent is required; therefore, the problem to be solved at present is to explore a process route for temozolomide, which is simple and convenient to operate, short in production period, high in yield and more suitable for industrial production.
Disclosure of Invention
In order to solve the problems of long route, unstable intermediate, need of chemical reagents with high toxicity and the like in the preparation process of temozolomide in the prior art, the invention provides a novel temozolomide intermediate compound and a novel method for preparing temozolomide by using the compound; the method has the advantages of short reaction route, simple and convenient operation, milder reaction, economy, environmental protection and high yield, and is suitable for industrial production.
The invention is realized by the following technical scheme:
a temozolomide intermediate compound represented by formula VII:
a preparation method of a temozolomide intermediate compound VII comprises the following steps: adding a compound V into an organic solvent under the protection of nitrogen, adding alkali, cooling and stirring, adding a compound VI p-nitrophenyl chloroformate into the reaction solution, continuing to react at low temperature, and obtaining a compound VII after the detection reaction is finished, wherein the synthetic route is as follows:
preferably, the base is one or two selected from triethylamine, pyridine, potassium carbonate, N-methylmorpholine and N, N-diisopropylethylamine, and particularly preferably triethylamine.
Preferably, the organic solvent for reaction is selected from one or a mixture of dichloromethane, chloroform, tetrahydrofuran and acetonitrile, and dichloromethane is particularly preferred.
In a preferred scheme, the reaction temperature is-15 ℃ to 5 ℃.
In a preferred scheme, the feeding molar ratio of the reaction compound V, the compound VI and the base is as follows: 1: 1.0-2.0: 1.1-2.0, and particularly preferably 1:1.1: 1.2.
In a preferred embodiment, after the reaction is finished, a post-treatment operation is required, specifically: and (4) carrying out suction filtration under reduced pressure, washing a filter cake with dichloromethane and water, and drying to obtain an intermediate VII.
Wherein the intermediate compound V is prepared as follows:
the preparation method of the compound V comprises the following steps: adding the compound IV into a mixed acid solvent, controlling the temperature and stirring to dissolve the solid, and continuously stirring until the reaction is finished to obtain an intermediate V, wherein the synthetic route is as follows:
preferably, the mixed acid solvent is selected from one or a combination of a concentrated hydrochloric acid glacial acetic acid mixed system, a sulfuric acid glacial acetic acid mixed system and a trifluoroacetic acid glacial acetic acid mixed system, and particularly preferably a concentrated sulfuric acid glacial acetic acid mixed system.
In a preferred scheme, the reaction temperature is 55-70 ℃.
In a preferred embodiment, after the reaction is finished, a post-treatment operation is required, specifically: cooling the reaction solution to room temperature, adding water, stirring and pulping, cooling to about 0 ℃, performing suction filtration, washing a filter cake with ice water, and drying to obtain an intermediate V.
Wherein the intermediate compound IV is prepared as follows:
adding a compound II into a mixed solution of acid and an organic solvent, stirring and dissolving, adding methylhydrazine, reacting at room temperature, evaporating an organic phase after the reaction is finished, and adding a mixture of acid and alcohol until the reaction is finished to obtain a compound IV, wherein the synthetic route is as follows:
preferably, the acid may be one of glacial acetic acid, hydrochloric acid, concentrated sulfuric acid, or a combination thereof, wherein glacial acetic acid is particularly preferred.
Preferably, the organic solvent is selected from one or a combination of dichloromethane, trichloromethane, tetrahydrofuran and 1, 2-dichloroethane.
Preferably, the mixed system of the acid and the alcohol is one or a combination of a trifluoroacetic acid/methanol mixed system, a hydrochloric acid/methanol mixed system and a glacial acetic acid/methanol mixed system.
In a preferable embodiment, the volume ratio of the acid to the organic solvent is 1: 2.0-4.0, and particularly preferably 1: 3.0.
Preferably, the volume ratio of the acid to the alcohol in the mixed system of the acid and the alcohol is as follows: vAcid(s):VAlcohol(s)=1:3.0~4.0。
In a preferable embodiment, the feeding molar ratio of the compound II to the compound III is 1: 1.0-2.0, and particularly preferably 1: 1.2.
In a preferred embodiment, after the reaction is finished, a post-treatment operation is required, specifically: cooling in ice bath, filtering under reduced pressure, washing the filter cake with glacial methanol, concentrating the liquid phase and removing the organic solvent to obtain a compound IV. .
The application of the compound VII in preparing temozolomide.
The compound VII is used for preparing temozolomide, and the preparation method comprises the following steps: adding a compound VII into an organic solvent, and stirring at a controlled temperature to obtain temozolomide, wherein the synthetic route is as follows:
preferably, the organic solvent is selected from one or a combination of N, N-dimethylformamide, tetrahydrofuran, toluene and acetonitrile, and N, N-dimethylformamide is particularly preferred.
In a preferable scheme, the reaction temperature is 40-70 ℃.
In a preferred embodiment, after the reaction is finished, a post-treatment operation is required, specifically: cooling to about-15 ℃ after the reaction is finished, carrying out vacuum filtration, washing a filter cake with glacial ethanol, and drying to obtain temozolomide
Compared with the prior art, the invention has the following technical effects:
1. the novel temozolomide intermediate compound VII is provided, the temozolomide can be prepared by one-step cyclization, no oxidative cyclization reagent is needed in cyclization reaction, no dimerization impurity is generated, the whole synthesis method is simple and convenient to operate, the reaction yield is high, and the purity of the obtained product is high;
2. the invention also provides a novel preparation method of temozolomide, the whole synthesis method is simple and convenient to operate, high in reaction yield, high in purity of the obtained product and suitable for industrial production.
In conclusion, the invention provides a novel method for preparing temozolomide, which avoids using dangerous chemical reagents, ensures that a synthesized intermediate does not generate dimeric impurities, has milder reaction, is economic and environment-friendly, has higher yield, and is suitable for industrial production.
Detailed Description
The invention is further illustrated by the following examples. It should be properly understood that: the examples of the present invention are intended to be illustrative only and not to be limiting, and therefore, the present invention is intended to be simply modified within the scope of the present invention as claimed.
The structure of the novel compound obtained by the invention is confirmed:
structural characterization of Compound IV
High resolution mass spectrum of compound IV: ESI-MS: M/z 151.0700[ M + H ]]+;1H NMR(500MHz,CDCl3)δ8.00(s,1H),7.23(s,1H),3.18(s,3H);13C-NMR(125MHz,CDCl3)δ148.96,128.70,114.69,69.03,34.58.
Structural characterization of Compound VII
High resolution mass spectrum of compound VII: ESI-MS: M/z 334.0904[ M + H ]]+;1H-NMR(500MHz,CDCl3)δ8.79(s,1H),8.26-8.19(m,2H),7.17-7.11(m,2H),6.78(s,2H),6.19(s,1H),3.15(s,3H);13C-NMR(125MHz,CDCl3)δ164.14,163.87,151.31,146.20,138.40,136.80,131.10,125.26,121.88,34.58.
Preparation of Compound IV
Example 1
Dissolving compound II (50.0g, 0.24mol) in a mixed solution of 120mL of glacial acetic acid and 360mL of dichloromethane, stirring to dissolve the compound II, slowly dripping methylhydrazine (13.43g, 0.29mol) into the reaction system, reacting at room temperature, detecting the end of the reaction, spin-drying dichloromethane, adding 240mL of methanol and 60mL of trifluoroacetic acid, and stirring to react. Cooling in ice bath, filtering under reduced pressure, washing the filter cake with glacial methanol, concentrating and removing the organic solvent to obtain a compound IV with the yield of 92.5 percent and the HPLC purity of 99.92 percent.
Example 2
Dissolving compound II (50.0g, 0.24mol) in a mixed solution of 120mL of glacial acetic acid and 240mL of trichloromethane, stirring for dissolving, slowly dripping methylhydrazine (11.06g, 0.24mol) into a reaction system, reacting at room temperature, detecting the end of the reaction, spin-drying the trichloromethane, adding 200mL of methanol and 60mL of hydrochloric acid, and stirring for reacting. Reducing the temperature in an ice bath, filtering under reduced pressure, washing a filter cake by using glacial methanol, concentrating and removing the organic solvent to obtain a compound IV with the yield of 88.1 percent and the HPLC purity of 99.87 percent.
Example 3
Dissolving compound II (50.0g, 0.24mol) in a mixed solution of 120mL of glacial acetic acid and 300mL of tetrahydrofuran, stirring to dissolve the compound II, slowly dripping methylhydrazine (22.11g, 0.48mol) into the reaction system, reacting at room temperature, detecting the end of the reaction, spin-drying the tetrahydrofuran, adding 180mL of methanol and 60mL of glacial acetic acid, and stirring to react. Cooling in ice bath, filtering under reduced pressure, washing filter cake with glacial methanol, concentrating and removing organic solvent to obtain compound IV with yield of 86.3% and HPLC purity of 99.79%.
Example 4 (methylhydrazine, outside upper limit)
Dissolving compound II (50.0g, 0.24mol) in a mixed solution of 120mL of glacial acetic acid and 480mL of 1, 2-dichloroethane, stirring to dissolve, slowly dripping methylhydrazine (24.32g, 0.53mol) into the reaction system, reacting at room temperature, detecting the reaction is finished, spin-drying 1, 2-dichloroethane, adding 200mL of methanol and 60mL of trifluoroacetic acid, and stirring to react. Reducing the temperature in an ice bath, filtering under reduced pressure, washing a filter cake by using glacial methanol, concentrating and removing the organic solvent to obtain a compound IV with the yield of 82.1 percent and the HPLC purity of 99.68 percent.
Preparation of Compound V
Example 5
Dissolving a compound IV (15.0g, 0.1mol) in a mixed solution containing 50mL of concentrated hydrochloric acid and 25mL of glacial acetic acid, heating to 60-65 ℃ until the compound IV is completely dissolved, reacting at a constant temperature, cooling to room temperature after monitoring the reaction, adding 100mL of water, stirring and pulping, cooling to 0 ℃, performing suction filtration, washing a filter cake with ice water, and drying to obtain an intermediate V, wherein the yield is 98.4% and the HPLC purity is 99.91%.
Example 6
Dissolving a compound IV (15.0g, 0.1mol) in a mixed solution containing 50mL of concentrated sulfuric acid and 25mL of glacial acetic acid, heating to 55-60 ℃ until the compound IV is completely dissolved, reacting at a constant temperature, cooling to room temperature after monitoring the reaction, adding 100mL of water, stirring and pulping, cooling to 0 ℃, performing suction filtration, washing a filter cake with ice water, and drying to obtain an intermediate V, wherein the yield is 96.4%, and the HPLC purity is 99.88%.
Example 7
Dissolving a compound IV (15.0g, 0.1mol) in a mixed solution containing 50mL of trifluoroacetic acid and 25mL of glacial acetic acid, heating to 65-70 ℃ until the compound IV is completely dissolved, reacting at a constant temperature, cooling to room temperature after monitoring the reaction, adding 100mL of water, stirring and pulping, cooling to 0 ℃, performing suction filtration, washing a filter cake with ice water, and drying to obtain an intermediate V, wherein the yield is 95.4%, and the HPLC purity is 99.84%.
Preparation of Compound VII
Example 8
Adding the intermediate V (25.8g, 0.15mol), 600mL of dichloromethane and triethylamine (18.21g, 0.18mol) into a reaction bottle, introducing nitrogen for protection, cooling to-5 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (33.25g, 0.165mol) dissolved in methylene chloride was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, filter cakes are washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 98.9 percent, and the HPLC purity is 99.88 percent.
Example 9
Adding the intermediate V (25.8g, 0.15mol), 600mL of trichloromethane and triethylamine (16.70g, 0.165mol) into a reaction bottle, introducing nitrogen for protection, cooling to-15 ℃, and stirring. 400mL of p-nitrophenyl chloroformate (33.25g, 0.165mol) dissolved in chloroform was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 96.9 percent, and the HPLC purity is 99.83 percent.
Example 10
Adding the intermediate V (25.8g, 0.15mol), tetrahydrofuran 600mL and triethylamine (30.36g, 0.30mol) into a reaction bottle, introducing nitrogen for protection, cooling to 5 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (33.25g, 0.165mol) dissolved in tetrahydrofuran was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 94.5 percent, and the HPLC purity is 99.78 percent.
Example 11
Adding the intermediate V (25.8g, 0.15mol), acetonitrile 600mL and triethylamine (15.18g, 0.15mol) into a reaction bottle, introducing nitrogen for protection, cooling to 0 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (33.25g, 0.165mol) dissolved in acetonitrile was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 90.5 percent, and the HPLC purity is 99.79 percent.
Example 12
Adding the intermediate V (25.8g, 0.15mol), 600mL of dichloromethane and triethylamine (33.40g, 0.33mol) into a reaction bottle, introducing nitrogen for protection, cooling to 0 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (33.25g, 0.165mol) dissolved in methylene chloride was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, and a filter cake is washed by dichloromethane and water and dried to obtain an intermediate II with yield of 88.2% and HPLC purity of 99.72%.
Example 13
Adding the intermediate V (25.8g, 0.15mol), 600mL of dichloromethane and pyridine (14.24g, 0.18mol) into a reaction bottle, introducing nitrogen for protection, cooling to-5 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (30.23g, 0.15mol) dissolved in methylene chloride was slowly added dropwise to the reaction system. After the addition, the reaction was continued for 4 hours and left at room temperature for 18 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 94.4 percent, and the HPLC purity is 99.82 percent.
Example 14
Adding the intermediate V (25.8g, 0.15mol), 600mL of dichloromethane and potassium carbonate (24.88g, 0.18mol) into a reaction bottle, introducing nitrogen for protection, cooling to-5 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (60.47g, 0.30mol) dissolved in methylene chloride was slowly added dropwise to the reaction system. After the dropwise addition, the reaction was continued for 6 hours, and the reaction mixture was left at room temperature for 20 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 93.6 percent, and the HPLC purity is 99.78 percent.
Example 15
Adding the intermediate V (25.8g, 0.15mol), 600mL of dichloromethane and N, N-diisopropylethylamine (23.26g, 0.18mol) into a reaction bottle, introducing nitrogen for protection, cooling to-5 ℃ and stirring. 400mL of p-nitrophenyl chloroformate (66.51g, 0.33mol) dissolved in methylene chloride was slowly added dropwise to the reaction system. After the dropwise addition, the reaction was continued for 6 hours, and the reaction mixture was left at room temperature for 20 hours. Vacuum filtration is carried out, the filter cake is washed by dichloromethane and water, and the intermediate II is obtained after drying, the yield is 86.3 percent, and the HPLC purity is 99.70 percent.
Preparation of temozolomide
Example 16
Dissolving the intermediate VII (20g, 0.06mol) in 200mL of N, N-dimethylformamide, heating to 50 ℃, stirring at a constant temperature, reacting, cooling to-15 ℃ after detection reaction, performing vacuum filtration, washing a filter cake with glacial ethanol, and performing vacuum drying at 40 ℃ to obtain temozolomide, wherein the yield is 98.6%, and the HPLC purity is 99.89%. One or a combination of toluene and acetonitrile, and N, N-dimethylformamide is particularly preferred
Example 17
Dissolving the intermediate VII (20g, 0.06mol) in 200mL tetrahydrofuran, heating to 40 ℃, stirring at constant temperature, reacting, cooling to-10 ℃ after detection reaction, carrying out vacuum filtration, washing a filter cake with glacial ethanol, and carrying out vacuum drying at 40 ℃ to obtain temozolomide, wherein the yield is 96.6%, and the HPLC purity is 99.82%.
Example 18
Dissolving the intermediate VII (20g, 0.06mol) in 200mL of toluene, heating to 70 ℃, stirring at constant temperature for reaction, cooling to-15 ℃ after detection reaction, carrying out vacuum filtration, washing a filter cake with glacial ethanol, and carrying out vacuum drying at 40 ℃ to obtain temozolomide, wherein the yield is 94.5%, and the HPLC purity is 99.79%.
Example 19
Dissolving the intermediate VII (20g, 0.06mol) in 200mL acetonitrile, heating to 35 ℃, stirring at constant temperature for reaction, cooling to-15 ℃ after detection reaction, carrying out vacuum filtration, washing a filter cake with glacial ethanol, and carrying out vacuum drying at 40 ℃ to obtain temozolomide, wherein the yield is 93.8%, and the HPLC purity is 99.77%.
Comparative examples
5-aminoimidazole-4-carboxamide (80g, 634.32mmol), dichloromethane (1920mL), and triethylamine (176.82mL, 1268.63mmol) were sequentially added to a 5L three-necked round-bottomed flask equipped with a thermometer, and the mixture was stirred at 25 ℃ for 10 minutes to lower the temperature of the reaction system to 0 ℃ or lower, after 10 minutes, 4-nitrophenylchloroformate (255.71g,1268.36mmol) dissolved in 1280mL dichloromethane was added dropwise, and after 4 hours of reaction at 0 ℃ or lower, the temperature was controlled at 25 ℃ for 18 hours. And (3) leaching the reaction solution by using a Buchner funnel, pulping and washing the obtained filter cake for 1 hour by using a mixed solution of 1000mL of dichloromethane and 200mL of water, leaching again, washing the filter cake by using dichloromethane, and airing at normal temperature to obtain a yellow solid product, wherein the yield is 80.6%, and the HPLC purity is 97.72%.
To a 50mL round bottom flask was added in sequence intermediate 2(30g,103.02mmol), solvent tetrahydrofuran 240mL, and after stirring for 10 minutes, 33% methylamine alcohol solution (12.6mL,103.02mmol) was added slowly and the temperature was controlled at 25 ℃ for 5 hours. And (3) carrying out suction filtration on the reaction solution by using a Buchner funnel, washing the obtained filter cake by using 300mL of diethyl ether and 200mL of acetone mixed solution (diethyl ether: acetone is 3:2), stirring and pulping for 1 hour, washing the suction filtration filter cake by using acetone, and airing to obtain a light yellow product, wherein the yield is 76.6%, and the HPLC purity is 97.75%.
A1L three-necked round-bottomed flask was taken, and lithium chloride monohydrate (373.03g,6175mmol), glacial acetic acid (29mL), and water (290mL) were added in this order. Stirred at room temperature for 30 minutes. Adding the intermediate 3(29g, 158.32mmol), stirring at normal temperature for 30 minutes, placing the reaction bottle in a cooling circulating pump, controlling the temperature below 0 ℃, cooling for 10 minutes, dropwise adding an aqueous solution of sodium nitrite (14.5g dissolved in 58ml of water), controlling the temperature within-10-5 ℃, stirring the reaction mixture liquid at 0-5 ℃ for one hour, adding I2(4.00g,15.8mmol), reacting at normal temperature for 2 hours, dissolving an aqueous solution of sodium thiosulfate (29g in 290ml of water), and stirring for 20 minutes to finish the reaction. Extracting with 5L of dichloromethane for 8-10 times each time, filtering the extract, performing rotary evaporation concentration to obtain a solution, concentrating to 100ml of a solvent, and performing suction filtration to obtain a finished product of temozolomide pink, wherein the yield is 80.6% and the HPLC purity is 97.82%.
Claims (9)
2. the intermediate compound VII of claim 1, wherein the process of preparation comprises the steps of: adding a compound V into an organic solvent under the protection of nitrogen, adding alkali, cooling and stirring to dissolve a solid, adding a compound VI, namely p-nitrophenyl chloroformate into a reaction solution, continuing to react at a low temperature, and obtaining a compound VII after the detection reaction is finished, wherein the reaction route is as follows:
3. the preparation method according to claim 2, wherein the base is selected from one or a combination of triethylamine, pyridine, potassium carbonate, N-methylmorpholine, N-diisopropylethylamine.
4. The preparation method according to claim 2, wherein the compound V, the compound VI and the base are fed in a molar ratio of: 1: 1.0-2.0: 1.1-2.0.
5. The preparation method according to claim 2, wherein the organic solvent is selected from one or a combination of dichloromethane, chloroform, tetrahydrofuran and acetonitrile; the reaction temperature is-15 ℃ to 5 ℃.
6. Use of compound v II according to claim 1 for the preparation of temozolomide.
8. the preparation method according to claim 7, wherein the organic solvent is selected from one or a combination of N, N-dimethylformamide, tetrahydrofuran, toluene and acetonitrile.
9. The method according to claim 7, wherein the reaction temperature is 40 to 70 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010205396.9A CN113493417B (en) | 2020-03-22 | 2020-03-22 | Temozolomide intermediate compound VII |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010205396.9A CN113493417B (en) | 2020-03-22 | 2020-03-22 | Temozolomide intermediate compound VII |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113493417A true CN113493417A (en) | 2021-10-12 |
CN113493417B CN113493417B (en) | 2024-03-15 |
Family
ID=77993845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010205396.9A Active CN113493417B (en) | 2020-03-22 | 2020-03-22 | Temozolomide intermediate compound VII |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113493417B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102659789A (en) * | 2011-04-27 | 2012-09-12 | 四川科瑞德凯华制药有限公司 | Method preparing temozolomide in one-pot mode and refining method of temozolomide |
CN103626772A (en) * | 2012-08-24 | 2014-03-12 | 国药一心制药有限公司 | Synthetic method for temozolomide and intermediate |
CN109467534A (en) * | 2017-09-07 | 2019-03-15 | 湖北半天制药有限公司 | A kind of synthetic method of Temozolomide intermediate |
-
2020
- 2020-03-22 CN CN202010205396.9A patent/CN113493417B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102659789A (en) * | 2011-04-27 | 2012-09-12 | 四川科瑞德凯华制药有限公司 | Method preparing temozolomide in one-pot mode and refining method of temozolomide |
CN103626772A (en) * | 2012-08-24 | 2014-03-12 | 国药一心制药有限公司 | Synthetic method for temozolomide and intermediate |
CN109467534A (en) * | 2017-09-07 | 2019-03-15 | 湖北半天制药有限公司 | A kind of synthetic method of Temozolomide intermediate |
Non-Patent Citations (3)
Title |
---|
GAVIN D. BROWN,等: "Antitumor Imidazotetrazines. 40.1 Radiosyntheses of [4-11C-Carbonyl]- and [3-N-11C-Methyl]-8-carbamoyl-3-methylimidazo[5, 1-d]-1, 2, 3, 5-tetrazin-4(3H)-one (Temozolomide) for Positron Emission Tomography (PET) Studies", 《J. MED. CHEM.》, vol. 45, pages 5448 - 5457, XP002637804, DOI: 10.1021/jm020921f * |
MARTIN J. WANNER,等: "A new synthesis of temozolomide", 《J. CHEM. SOC., PERKIN TRANS. 1》, pages 1877 - 1880 * |
YONGFENG WANG,等: "Antitumor Imidazotetrazines. 35. New Synthetic Routes to the Antitumor Drug Temozolomide", 《J. ORG. CHEM.》, vol. 62, pages 7288 - 7294 * |
Also Published As
Publication number | Publication date |
---|---|
CN113493417B (en) | 2024-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106496187A (en) | A kind of synthetic method for preparing PARP inhibitor Niraparib | |
CN102351778A (en) | Preparation method of arbidol hydrochloride | |
CN110183445B (en) | Synthetic method of moxifloxacin and derivatives thereof | |
CN109384827A (en) | A kind of budesonide industrialized process for preparing | |
EP3527556B1 (en) | Method for preparing deuterated imidazole diketone compound | |
CN114805327A (en) | Intermediate for thiohydantoin medicine and preparation method and application thereof | |
CN112010913B (en) | Preparation method of 4-deoxy daunorubicin | |
EP3692030B1 (en) | Process for the preparation of ridinilazole using acid addition salts | |
CN111675653A (en) | Preparation method and application of impurities of 4-aminoquinoline compound | |
CN113493417A (en) | Temozolomide intermediate compound VII | |
CN106279155A (en) | Impurity reference substance of tadanafil and preparation method thereof | |
CN113493418A (en) | Temozolomide intermediate compound IV | |
CN113493458A (en) | Preparation method of temozolomide | |
CN115215820A (en) | Preparation method of cabazitaxel impurity F | |
CN111574520B (en) | Riagliptin intermediate compound V | |
CN114057767B (en) | Preparation method of temsirolimus | |
CN111574463B (en) | Rivastigmine intermediate compound IV | |
CN113372375B (en) | Preparation method of temsirolimus intermediate | |
CN110684000B (en) | Process for preparing benzofuran derivatives | |
CN110563721A (en) | Preparation method of azasetron hydrochloride | |
CN114539288B (en) | Preparation method of everolimus | |
CN112262124A (en) | Process for producing alpha-azidoaniline derivative or alpha, alpha' -diazide derivative | |
CN107216360B (en) | A method of preparing rope Citropten | |
CN115197281B (en) | Preparation method of etoposide intermediate | |
CN114560845B (en) | Crystal form alpha of quinoline compound, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |